Clinical Trial Goal
To find out if the combination of obinutuzumab, venetoclax, and zanubrutinib is safe and works well to treat CLL or SLL that has not yet been treated
You may be able to join this trial if you:
- Are 18 years old or older
- Have CLL or SLL and have had little or no treatment
- Do not have Richter’s transformation
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Obinutuzumab is a monoclonal antibody that targets CD20 on certain cells.
Venetoclax is a small molecule inhibitor that blocks BCL2 in certain cells.
Zanubrutinib is a small molecule inhibitor that blocks BTK in certain cells.
You’ll get:
Venetoclax is a small molecule inhibitor that blocks BCL2 in certain cells.
Zanubrutinib is a small molecule inhibitor that blocks BTK in certain cells.
You’ll get:
- Obinutuzumab – Given as an intravenous (IV) infusion 3 – 4 times during the first month, then 1 time each month
- Venetoclax – A pill that you take by mouth each day starting in the third month
- Zanubrutinib – A pill that you take by mouth 2 times each day for 3 times during the first month, then 1 time each month
You may continue treatment for as long as the clinical trial doctors think it’s best for your health. You’ll have biopsies to see how well treatment is working. The clinical trial doctors will check your health for up to 1 year.
The Food and Drug Administration (FDA) has approved obinutuzumab and venetoclax to treat CLL. The FDA has approved zanubrutinib to treat mantle cell lymphoma (MCL). Using them together in this way to treat CLL or SLL that has not yet been treated is new and unproven.
Locations
Sponsors
collaborator: BeiGene USA, Inc., collaborator: Roche-Genentech, collaborator: Massachusetts General Hospital, lead: Memorial Sloan Kettering Cancer Center
